Cannabinoid Receptor Gene Polymorphisms and Cognitive Performance in Patients with Schizophrenia and Controls

Overview

Journal Braz J Psychiatry

Specialty Psychiatry

Date 2021 Jun 30

PMID 34190825

Citations 5

Authors

Rodrigo Ferretjans

Renan P de Souza

Bruna Panizzutti

Pamela Ferrari

Lucas Mantovani

Salvina M de Campos-Carli

Rafael R Santos

Fernanda C Guimaraes

Antonio L Teixeira

Clarissa S Gama

Joao V Salgado

Affiliations

Soon will be listed here.

Abstract

Objective: To test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia.

Methods: In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive performance in 69 patients with schizophrenia and 45 healthy controls. Neurocognition was assessed by the Brief Assessment of Cognition in Schizophrenia (BACS).

Results: We found a consistent association between CNR1 rs12720071 polymorphism and the cognitive performance of patients in several cognitive domains. Patients with C/C polymorphism presented significantly worse performance in motor speed, verbal fluency, attention/processing speed and reasoning/problem solving.

Conclusion: Although limited, our data support the hypothesis that CNR1 variations may be associated with the pathogenesis of cognitive deficits of schizophrenia.

Citing Articles

Clinical and cognitive outcomes in first-episode psychosis: focus on the interplay between cannabis use and genetic variability in endocannabinoid receptors.

Oscoz-Irurozqui M, Guardiola-Ripoll M, Almodovar-Paya C, Guerrero-Pedraza A, Hostalet N, Carrion M Front Psychol. 2024; 15:1414098.

PMID: 39193030 PMC: 11348434. DOI: 10.3389/fpsyg.2024.1414098.

Association Between the Endocannabinoid System-Related Gene Variants and Epilepsy.

Hosseinzadeh Anvar L, Moosavi S, Charsouei S, Zeinalzadeh N, Nikanfar M, Ahmadalipour A Mol Neurobiol. 2024; 61(11):8967-8974.

PMID: 38578355 DOI: 10.1007/s12035-024-04132-5.

Potential of olfactory neuroepithelial cells as a model to study schizophrenia: A focus on GPCRs (Review).

Sanchez-Florentino Z, Romero-Martinez B, Flores-Soto E, Serrano H, Montano L, Valdes-Tovar M Int J Mol Med. 2023; 53(1).

PMID: 38038161 PMC: 10712696. DOI: 10.3892/ijmm.2023.5331.

Neurocognitive Deficits in First-Episode and Chronic Psychotic Disorders: A Systematic Review from 2009 to 2022.

Tschentscher N, Woll C, Tafelmaier J, Kriesche D, Bucher J, Engel R Brain Sci. 2023; 13(2).

PMID: 36831842 PMC: 9954070. DOI: 10.3390/brainsci13020299.

Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Navarro D, Gasparyan A, Navarrete F, Torregrosa A, Rubio G, Marin-Mayor M Int J Mol Sci. 2022; 23(9).

PMID: 35563156 PMC: 9104141. DOI: 10.3390/ijms23094764.

References

Melis M, Pistis M . Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3276-85. PMC: 3481525. DOI: 10.1098/rstb.2011.0383. View

Akira S, Isshiki H, Sugita T, TANABE O, Kinoshita S, Nishio Y . A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 1990; 9(6):1897-906. PMC: 551896. DOI: 10.1002/j.1460-2075.1990.tb08316.x. View

Namipashaki A, Razaghi-Moghadam Z, Ansari-Pour N . The Essentiality of Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based Genetic Association Studies. Cell J. 2015; 17(2):187-92. PMC: 4503832. DOI: 10.22074/cellj.2016.3711. View

Barrett L, Fletcher S, Wilton S . Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci. 2012; 69(21):3613-34. PMC: 3474909. DOI: 10.1007/s00018-012-0990-9. View

Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva F, Bilbao A, Cippitelli A, Navarro M . The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2004; 40(1):2-14. DOI: 10.1093/alcalc/agh110. View

Heinrichs R, Zakzanis K . Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12(3):426-45. DOI: 10.1037//0894-4105.12.3.426. View

Castillo P, Younts T, Chavez A, Hashimotodani Y . Endocannabinoid signaling and synaptic function. Neuron. 2012; 76(1):70-81. PMC: 3517813. DOI: 10.1016/j.neuron.2012.09.020. View

Bossong M, Jansma J, van Hell H, Jager G, Oudman E, Saliasi E . Effects of δ9-tetrahydrocannabinol on human working memory function. Biol Psychiatry. 2012; 71(8):693-9. DOI: 10.1016/j.biopsych.2012.01.008. View

Fioravanti M, Carlone O, Vitale B, Cinti M, Clare L . A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev. 2005; 15(2):73-95. DOI: 10.1007/s11065-005-6254-9. View

10.

Skosnik P, Ranganathan M, DSouza D . Cannabinoids, working memory, and schizophrenia. Biol Psychiatry. 2012; 71(8):662-3. DOI: 10.1016/j.biopsych.2012.02.028. View

11.

Arevalo-Martin A, Garcia-Ovejero D, Rubio-Araiz A, Gomez O, Molina-Holgado F, Molina-Holgado E . Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2. Eur J Neurosci. 2007; 26(6):1548-59. DOI: 10.1111/j.1460-9568.2007.05782.x. View

12.

Insel T . Rethinking schizophrenia. Nature. 2010; 468(7321):187-93. DOI: 10.1038/nature09552. View

13.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

14.

Tandon R, Keshavan M, Nasrallah H . Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008; 102(1-3):1-18. DOI: 10.1016/j.schres.2008.04.011. View

15.

Bioque M, Cabrera B, Garcia-Bueno B, Mac-Dowell K, Torrent C, Saiz P . Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. J Psychiatr Res. 2016; 75:14-21. DOI: 10.1016/j.jpsychires.2016.01.002. View

16.

Ruiz-Contreras A, Delgado-Herrera M, Garcia-Vaca P, Almeida-Rosas G, Soria-Rodriguez G, Soriano-Bautista A . Involvement of the AATn polymorphism of the CNR1 gene in the efficiency of procedural learning in humans. Neurosci Lett. 2011; 494(3):202-6. DOI: 10.1016/j.neulet.2011.03.013. View

17.

Nuechterlein K, Barch D, Gold J, Goldberg T, Green M, Heaton R . Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004; 72(1):29-39. DOI: 10.1016/j.schres.2004.09.007. View

18.

Zhang P, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D . Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry. 2004; 9(10):916-31. DOI: 10.1038/sj.mp.4001560. View

19.

Dickinson D, Ramsey M, Gold J . Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007; 64(5):532-42. DOI: 10.1001/archpsyc.64.5.532. View

20.

Johnson J, Muhleman D, Macmurray J, Gade R, Verde R, Ask M . Association between the cannabinoid receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry. 1997; 2(2):169-71. DOI: 10.1038/sj.mp.4000246. View